Results 61 to 70 of about 2,227,737 (406)

Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.

Journal of the American Medical Association (JAMA), 2019
Importance In patients with heart failure and reduced ejection fraction (HFrEF), treatment with sacubitril-valsartan reduces N-terminal pro-b-type natriuretic peptide (NT-proBNP) concentrations. The effect of sacubitril-valsartan on cardiac remodeling is
MD JamesL.JanuzziJr, PhD MargaretF.Prescott, Mdmphmba JavedButler, Mdmhs G.MichaelFelker, MD AlanS.Maisel, KevinMcCague, PhD AlexanderCamacho, Mdmph IleanaL.Piña, MD RicardoA.Rocha, Mdmph AmilM.Shah, PharmD KristinM.Williamson, MD ScottD.Solomon, PrescottButler Felker Januzzi, Pina Maisel, Solomon Rocha, McCague, Camacho, Camacho McCague, CamachoRocha Williamson Butler, ButlerFelker Prescott, Rocha Maisel, Solomon Williamson   +21 more
semanticscholar   +1 more source

Contemporary management of heart failure in the elderly [PDF]

, 2019
The foundation of the treatment of heart failure with reduced ejection fraction is a number of pharmacotherapies shown to reduce morbidity and mortality in large randomised multinational clinical trials.
Jhund, Pardeep S., Osmanska, Joanna
core   +1 more source

Axial Muscle Size as a Strong Predictor of Death in Subjects With and Without Heart Failure

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background The impact of skeletal muscle size, quantified using simple noninvasive images routinely obtained during cardiac magnetic resonance imaging studies on mortality in the heart failure (HF) population is currently unknown.
Anupam Kumar, Bilal A. Ansari, Jessica Kim, Arpita Suri, Sowmya Gaddam, Sowjanya Yenigalla, Jagan M. Vanjarapu, Senthil Selvaraj, Dheera Tamvada, Jonathan Lee, Scott R. Akers, Julio A. Chirinos   +11 more
doaj   +1 more source

Predicting Ejection Fraction from Chest X-rays Using Computer Vision for Diagnosing Heart Failure [PDF]

arXiv, 2022
Heart failure remains a major public health challenge with growing costs. Ejection fraction (EF) is a key metric for the diagnosis and management of heart failure however estimation of EF using echocardiography remains expensive for the healthcare system and subject to intra/inter operator variability.
arxiv  

Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata

European Journal of Heart Failure, 2022
In older patients, guideline‐directed medical therapy (GDMT) for heart failure (HF) with reduced ejection fraction (
D. Stolfo, L. Lund, P. Becher, N. Orsini, T. Thorvaldsen, L. Benson, C. Hage, U. Dahlström, G. Sinagra, G. Savarese   +9 more
semanticscholar   +1 more source

Similarity-based prediction of Ejection Fraction in Heart Failure Patients [PDF]

arXiv, 2022
Biomedical research is increasingly employing real world evidence (RWE) to foster discoveries of novel clinical phenotypes and to better characterize long term effect of medical treatments. However, due to limitations inherent in the collection process, RWE often lacks key features of patients, particularly when these features cannot be directly ...
arxiv  

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction

Circulation, 2020
Supplemental Digital Content is available in the text. Background: Many patients with heart failure and reduced ejection fraction (HFrEF) have chronic kidney disease that complicates pharmacological management and is associated with worse outcomes.
P. Jhund, S. Solomon, K. Docherty, Hiddo J. L. Heerspink, I. Anand, M. Böhm, V. Chopra, R. D. de Boer, Akshay S. Desai, J. Ge, M. Kitakaze, Bela Merkley, E. O’Meara, M. Shou, S. Tereshchenko, S. Verma, P. N. Vinh, S. Inzucchi, L. Køber, M. Kosiborod, F. Martinez, P. Ponikowski, M. Sabatine, O. Bengtsson, A. Langkilde, M. Sjöstrand, J. McMurray   +26 more
semanticscholar   +1 more source

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.

Circulation, 2019
Outcome trials in patients with type 2 diabetes mellitus have demonstrated reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 inhibitors.
M. Nassif, Sheryl L. Windsor, F. Tang, Yevgeniy Khariton, M. Husain, S. Inzucchi, D. McGuire, B. Pitt, B. Scirica, B. Austin, M. Drazner, Michael W Fong, M. Givertz, R. Gordon, R. Jermyn, S. Katz, S. Lamba, D. Lanfear, S. Larue, J. Lindenfeld, M. Malone, K. Margulies, R. Mentz, R. Mutharasan, M. Pursley, G. Umpierrez, M. Kosiborod, A. Malik, Nannette Wenger, Modele O Ogunniyi, P. Vellanki, B. Murphy, J. Newman, J. Hartupee, Charu Gupta, Marcela Goldsmith, Paramdeep S. Baweja, M. Montero, S. Gottlieb, M. Costanzo, Thanh Hoang, A. Warnock, L. Allen, Wilson Tang, Horng H. Chen, J. M. Cox   +45 more
semanticscholar   +1 more source

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial [PDF]

Background: Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse cardiovascular events (MACE) in people with overweight or obesity, but the effects of this drug on outcomes in patients with atherosclerotic cardiovascular disease and ...
Abe M., Abhaichand R. K., Abhayaratna W. P., Abhyankar A., Abidin I. B. Z., Abou Assi H., Accini Mendoza J. L., Adas M., Agaiby J. M., Agarwal D. K., Agha M., Ahmed A., Ahtiainen P., Aigner E., Ajay N., Al-Karadsheh A., Al-Zoebi A., Ali N., Allison D. C., Allison R., Alpenidze D., Altuntas Y., Ambuj R., Amerena J., Anderson R. J., Ando T., Andrews R., Antonova E., Appel K. F., Arantes F. B., Araz M., Arbel Y., Arenas León J. L., Argyrakopoulou G., Ariani M., Arias Mendoza M. A., Arif A. A., Arneja J., Aroda V. R., Aronne L. J., Arstall M., Asamoah N., Asanin M., Audish H., Avram R., Badat A., Badiu C. V., Bakdash W., Bakiner O. S., Bandezi V. N., Bang L. H., Bansal S., Baranyai M., Barbarash O., Barber M., Barnum O., Barone Rochette G., Bashkin A., Baum S., Bays H. E., Bazzoni Ruiz A. E., Beckowski M., Beerachee Y., Bellary S., Belousova L., Berk M., Bernstein M., Berra C., Beshay I., Bhagwat A., Bhan A., Biggs W. C., Billings L., Bitar F., Block B., Bo S., Bogdanski P., Bolshakova O. O., Boshchenko A. A., Bosworth H., Buscemi S., Colhoun H. M., Deanfield J., Emerson S. S., Frenkel O., Goudev A., Hardt-Lindberg S., Hovingh G. K., Kahn S. E., Kosiborod M. N., Lang C. C., Lincoff A. M., Lingvay I., Pietilä M., Plutzky J., Rasmussen S., Ryan D., Scirica B. M., Urina-Triana M., Verma S., Weeke P. E.   +100 more
core   +9 more sources

Clinical characteristics and outcomes of heart failure with preserved, mildly reduced, and reduced ejection fraction: A 6-month follow-up study

Medical Journal of Babylon, 2022
Background and Objective: Heart failure is a major public health problem with 64.3 million people affected all over the world, and it is an important cause for hospital admission and mortality.
Goran Adnan Rahman, Abdulkareem Abdulwahab Al-Othman   +1 more
doaj   +1 more source